TNF and Crohn disease: Anti-TNF use was the main cost driver, accounting for 64% and 31% of the total cost of treatments for Crohn’s Disease (CD) and Ulcerative Colitis (UC), respectively, in the Netherlands, in seven academic and seven general hospitals [2].